SPAC2E1P3.01 Antibody

What is SPAC2E1P3.01 and why develop antibodies against it?

SPAC2E1P3.01 is a protein encoded in the Schizosaccharomyces pombe genome (Uniprot accession: Q9P7F4) . Antibodies against this protein are primarily used for studying protein function in fission yeast models. The polyclonal antibodies, such as CSB-PA885851XA01SXV, are developed by immunizing rabbits with recombinant SPAC2E1P3.01 protein from S. pombe strain 972 / ATCC 24843 . These antibodies enable researchers to detect the native protein in various experimental contexts, supporting investigations into cellular processes in this model organism.

What are the validated applications for SPAC2E1P3.01 antibody?

The primary validated applications include:

The antibody is specifically designed to ensure identification of the antigen in these contexts . When using this antibody for the first time in a particular experimental setup, it's advisable to perform titration experiments to determine the optimal working concentration for your specific conditions.

What are the recommended storage and handling procedures?

Upon receipt, SPAC2E1P3.01 antibody should be stored at -20°C or -80°C . Repeated freeze-thaw cycles should be avoided as they can compromise antibody function through protein denaturation and aggregation. For working aliquots, consider preparing smaller volumes to minimize freeze-thaw cycles. The antibody is typically supplied in a storage buffer containing 50% glycerol, 0.01M PBS (pH 7.4), and 0.03% Proclin 300 as a preservative .

How should I design control experiments when using SPAC2E1P3.01 antibody?

Designing appropriate controls is critical for antibody experiments. For SPAC2E1P3.01 antibody work, consider the following controls:

• Positive Control: Use purified recombinant SPAC2E1P3.01 protein or lysates from wild-type S. pombe known to express the protein.

• Negative Control: Include samples from:

  • S. pombe strains with SPAC2E1P3.01 gene deletion

  • Unrelated species samples to confirm specificity

• Technical Controls:

  • Primary antibody omission to assess secondary antibody specificity

  • Isotype control using a rabbit IgG polyclonal antibody at the same concentration

This multi-control approach mirrors the comprehensive control strategy used in antibody validation studies for other research antibodies, as demonstrated in the anti-CD3 antibody studies for diabetes research .

What factors affect SPAC2E1P3.01 antibody binding specificity and how can I optimize them?

Several factors can influence antibody specificity:

Similar optimization approaches have proven effective with other research antibodies. For example, studies with monoclonal antibodies for SARS-CoV-2 research demonstrated that careful optimization of these parameters significantly improved specificity and reduced background signals .

What is the recommended protocol for Western blot using SPAC2E1P3.01 antibody?

Sample Preparation:

• Harvest S. pombe cells in mid-log phase

• Lyse cells using glass bead disruption in lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, protease inhibitors)

• Clear lysate by centrifugation (14,000 × g, 15 min, 4°C)

• Determine protein concentration using Bradford assay

Western Blot Procedure:

• Separate proteins (20-50 μg/lane) on 10-12% SDS-PAGE

• Transfer to PVDF membrane (100V, 1 hour)

• Block membrane with 5% non-fat milk in TBS-T (1 hour, room temperature)

• Incubate with SPAC2E1P3.01 antibody (1:1000 dilution) in blocking buffer (overnight, 4°C)

• Wash 3× with TBS-T (10 min each)

• Incubate with HRP-conjugated anti-rabbit secondary antibody (1:5000, 1 hour, room temperature)

• Wash 3× with TBS-T (10 min each)

• Develop using ECL substrate and image

This protocol builds on established methodologies used in published antibody research studies, adapted specifically for the properties of the SPAC2E1P3.01 antibody .

How can I confirm the specificity of SPAC2E1P3.01 antibody in my experimental system?

To validate antibody specificity, implement the following methodology:

• Epitope Mapping Analysis: Similar to the approach used in cluster 1 antibody studies , perform competitive binding assays with recombinant fragments of SPAC2E1P3.01 to confirm epitope specificity.

• Genetic Validation:

  • Use CRISPR/Cas9 to generate SPAC2E1P3.01 knockout S. pombe strains

  • Compare antibody reactivity between wild-type and knockout samples

  • Absence of signal in knockout confirms specificity

• Mass Spectrometry Validation:

  • Perform immunoprecipitation with SPAC2E1P3.01 antibody

  • Analyze precipitated proteins by mass spectrometry

  • Confirm presence of SPAC2E1P3.01 peptides

• Immunofluorescence with Orthogonal Methods:

  • Compare antibody staining patterns with GFP-tagged SPAC2E1P3.01 expression

  • Colocalization confirms specificity

This multi-method validation approach is consistent with rigorous antibody validation strategies employed for therapeutic antibodies and other research applications .

How can SPAC2E1P3.01 antibody be used for protein complex identification?

Methodology for using the antibody in protein complex studies:

• Co-Immunoprecipitation Protocol:

  • Prepare S. pombe lysate in mild lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 0.5% NP-40, 1 mM EDTA, protease inhibitors)

  • Pre-clear lysate with Protein A/G beads (1 hour, 4°C)

  • Incubate pre-cleared lysate with 5 μg SPAC2E1P3.01 antibody overnight at 4°C

  • Add Protein A/G beads, incubate 4 hours at 4°C

  • Wash beads 5× with wash buffer

  • Elute protein complexes with 0.1 M glycine (pH 2.5)

  • Neutralize with 1 M Tris-HCl (pH 8.0)

  • Analyze by mass spectrometry or Western blot

• Proximity-Based Labeling:

  • Use SPAC2E1P3.01 antibody to validate BioID or APEX2 fusion protein experiments

  • Compare proteins identified through proximity labeling with those co-immunoprecipitated with the antibody

This approach leverages methodologies similar to those used for studying antibody-antigen interactions in therapeutic antibody research .

How can I quantify SPAC2E1P3.01 protein levels using the antibody?

For accurate protein quantification, employ the following methodology:

• Quantitative Western Blot:

  • Generate a standard curve using recombinant SPAC2E1P3.01 protein (10-100 ng)

  • Process standards alongside samples

  • Use fluorescently-labeled secondary antibodies for linear signal

  • Analyze with image analysis software (ImageJ)

• ELISA Quantification Method:

  • Coat plates with anti-SPAC2E1P3.01 capture antibody (1:1000, overnight, 4°C)

  • Block with 3% BSA in PBS (1 hour, room temperature)

  • Add samples and standards (recombinant protein)

  • Detect with biotinylated SPAC2E1P3.01 antibody and streptavidin-HRP

  • Develop with TMB substrate and read at 450 nm

  • Calculate concentration using standard curve

• Flow Cytometry Quantification:

  • Fix and permeabilize cells using methanol (-20°C, 15 min)

  • Block with 3% BSA in PBS (30 min, room temperature)

  • Incubate with SPAC2E1P3.01 antibody (1:500, 1 hour)

  • Wash and incubate with fluorescently-labeled secondary antibody

  • Analyze by flow cytometry using bead-based calibration

This quantitative approach builds on methodologies similar to those used for antibody-based quantification in clinical samples, as seen in the SARS-CoV-2 antibody research .

What are the considerations for epitope mapping of SPAC2E1P3.01 antibody?

For comprehensive epitope mapping, implement the following methodology:

• Peptide Array Analysis:

  • Design overlapping peptides (15-mers with 5 amino acid offset) spanning the entire SPAC2E1P3.01 sequence

  • Synthesize peptides on cellulose membrane or glass slide

  • Incubate with SPAC2E1P3.01 antibody (1:1000)

  • Detect bound antibody with labeled secondary antibody

  • Identify reactive peptides indicating epitope regions

• Mutagenesis Approach:

  • Generate alanine-scanning mutants of recombinant SPAC2E1P3.01

  • Express and purify mutant proteins

  • Test antibody binding by ELISA or Western blot

  • Identify critical residues for antibody binding

• Hydrogen-Deuterium Exchange Mass Spectrometry:

  • Compare deuterium uptake patterns of SPAC2E1P3.01 alone versus antibody-bound

  • Regions with decreased exchange rates when antibody-bound indicate epitope regions

This epitope mapping strategy builds on approaches used in therapeutic antibody development and characterization studies, such as the epitope analysis of cluster 1 antibodies and the structural studies of antibodies against SARS-CoV-2 and HCV .

How can I troubleshoot high background issues when using SPAC2E1P3.01 antibody?

When encountering high background, implement this methodological approach:

• Systematic Optimization Protocol:

  Issue	Methodological Solutions
  Non-specific binding	- Increase blocking time/concentration - Try different blocking agents (BSA, casein, normal serum) - Add 0.1-0.5% Triton X-100 to antibody diluent
  Secondary antibody issues	- Use highly cross-adsorbed secondary antibodies - Reduce secondary antibody concentration - Include 1-5% serum from host species of secondary antibody
  Sample preparation issues	- Optimize fixation conditions - Include additional washing steps - Pre-adsorb antibody with host tissue lysate
  Buffer compatibility	- Test different buffer systems (PBS vs. TBS) - Adjust salt concentration (150-500 mM NaCl) - Modify pH conditions (pH 7.2-8.0)

• Titration Experiments:

  • Perform serial dilutions of antibody (1:100 to 1:10,000)

  • Determine optimal concentration with highest signal-to-noise ratio

  • Consider reducing incubation time at higher concentrations

This troubleshooting approach is based on established methodologies used in antibody optimization studies, including those for therapeutic antibodies and research antibodies .

What methods can improve detection sensitivity when working with low-abundance SPAC2E1P3.01?

To enhance detection of low-abundance targets, implement these methodological approaches:

• Signal Amplification Methods:

  • Use tyramide signal amplification (TSA) protocol:

    • Dilute primary antibody 1:2000-1:5000

    • Use HRP-conjugated secondary antibody at 1:1000

    • Incubate with tyramide-fluorophore for 5-10 minutes

    • Expected 10-50× signal enhancement

• Sample Enrichment Strategies:

  • Immunoprecipitate SPAC2E1P3.01 before analysis

  • Use subcellular fractionation to concentrate target compartment

  • Apply protein concentration techniques (TCA precipitation)

• Enhanced Detection Systems:

  • Use highly-sensitive ECL substrates for Western blot

  • Apply quantum dot-conjugated secondary antibodies

  • Implement automated image analysis with background correction

This sensitivity enhancement approach builds on methodologies similar to those used in low-abundance protein detection systems, such as those developed for serological antibody detection and single-domain antibody research .

How does the performance of rabbit polyclonal SPAC2E1P3.01 antibody compare to other species-derived antibodies?

When comparing antibody performance across species, consider these methodological insights:

This comparative analysis is informed by research on antibody development strategies across species, including studies on camelid single-domain antibodies and therapeutic antibody engineering .

What methodological approaches can integrate SPAC2E1P3.01 antibody with advanced imaging techniques?

For integrating this antibody with advanced imaging, implement these methodologies:

• Super-Resolution Microscopy Protocol:

  • Fix S. pombe cells with 4% paraformaldehyde (15 min, room temperature)

  • Permeabilize with 0.1% Triton X-100 (10 min)

  • Block with 5% BSA in PBS (1 hour)

  • Incubate with SPAC2E1P3.01 antibody (1:500, overnight, 4°C)

  • Wash 3× with PBS

  • Incubate with highly cross-adsorbed fluorescent secondary antibody (1:1000, 1 hour)

  • Mount in specialized mounting medium (e.g., ProLong Glass)

  • Image using STORM, PALM, or SIM techniques

• Correlative Light and Electron Microscopy (CLEM):

  • Culture cells on gridded coverslips

  • Perform immunofluorescence with SPAC2E1P3.01 antibody

  • Image fluorescence signal

  • Process same sample for EM with nanogold-conjugated secondary antibodies

  • Correlate fluorescence and EM images

• Live-Cell Imaging Strategies:

  • Use cell-permeable fluorescent nanobodies against SPAC2E1P3.01

  • Validate localization patterns using fixed-cell immunofluorescence with the antibody

These advanced imaging approaches build on methodologies employed in structural and functional studies of antibodies, including those used in therapeutic antibody research and molecular characterization studies .

What methodological considerations ensure reproducible results with SPAC2E1P3.01 antibody across different research groups?

To maximize reproducibility, implement these methodological practices:

• Standardized Reporting Protocol:

  • Document complete antibody information:

    • Catalog number (CSB-PA885851XA01SXV)

    • Lot number

    • Host species (Rabbit)

    • Clonality (Polyclonal)

    • Immunogen (Recombinant S. pombe SPAC2E1P3.01 protein)

  • Report all experimental conditions in detail

  • Include images of full blots with molecular weight markers

• Validation Requirements:

  • Perform specificity validation with appropriate controls

  • Test multiple lots if used in long-term projects

  • Share validation data through repositories or supplements

• Material Sharing Practices:

  • Provide detailed protocols via protocols.io or similar platforms

  • Share positive control samples when possible

  • Document exact buffer compositions and incubation times

This reproducibility framework builds on best practices developed from therapeutic antibody research and antibody validation initiatives in the broader research community.

How should researchers address potential cross-reactivity of SPAC2E1P3.01 antibody with human proteins?

When investigating cross-reactivity concerns, implement this methodological approach:

• Cross-Reactivity Assessment Protocol:

  • Perform sequence homology analysis between S. pombe SPAC2E1P3.01 and human proteome

  • Test antibody against human cell lysates from multiple tissue types

  • Conduct pre-adsorption experiments with human proteins showing sequence similarity

• Specificity Enhancement Strategy:

  • Pre-adsorb antibody with human protein extracts before use

  • Increase stringency of washing steps

  • Use alternative detection methods for confirmation

• Reporting Framework:

  • Document all cross-reactivity testing performed

  • Report any identified cross-reactive proteins

  • Include appropriate disclaimers in publications

This cross-reactivity assessment methodology draws on approaches similar to those used in therapeutic antibody development and epitope analysis studies where species cross-reactivity is a critical consideration.